Effect of heparin-bonded pulmonary artery catheters on the activated coagulation time

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 12, Issue 5, 1998, Pages 533-535

  McNulty, Stephen E ^a,b   Maguire, David P ^a   Thomas, Ralph E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Activated coagulation time; Heparin bonded; Pulmonary artery catheter

Indexed keywords

HEPARIN;

ARTERY CATHETER; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

EID: 0031714812     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(98)90096-9     Document Type: Article

References (16)

1. Gravlee GP, Case LD, Angert KC, et al: Variability of the activated coagulation time. Anesth Analg 67:469-472, 1988
2. Jobes DR, Ellison N, Campbell FW: Limit(ation)s for ACT. Anesth Analg 69:142-144, 1989
3. Bonfiglio MF, Traeger SM, Kier KL, et al: Thrombocytopenia in intensive care patients: A comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 29:835-842, 1995
4. Kim YL, Richman KA, Marshall BE: Thrombocytopenia associated with Swan-Ganz catheterization in patients. Anesthesiology 53:261-262, 1980
5. Plate NA, Valuev LI: On the interaction of heparin-containing polymers with plasma proteins and blood. Thromb Res 27:131-141, 1982
6. Weiss BM, von Segesser LK, Turina MI, et al: Perioperative course and recovery after heparin-coated cardiopulmonary bypass: Low-dose versus high-dose heparin management. J Cardiothorac Vasc Anesth 10:464-470, 1996
7. Liu LS, Ito Y, Imanishi Y: Synthesis and antithrombogenicity of heparinized polyurethanes with intervening spacer chains of various kinds. Biomaterials 12:390-396, 1991
8. Gravlee GP, Whitaker CL, Mark LJ, et al: Baseline activated coagulation time should be measured after surgical incision. Anesth Analg 71:549-553, 1990
9. Despotis GJ, Summerfield AL, Joist JH, et al: Comparison of activated coagulation time and whole-blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108:1076-1082, 1994
10. Martindale SJ, Shayevitz JR, D'Errico C: The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 10:458-463, 1996
11. Moorehead MT, Westengard JC, Bull BS: Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 63:394-398, 1984
12. Ammar T, Fisher CF, Sarier K, Coller BS: The effects of thrombocytopenia on the activated coagulation time. Anesth Analg 83:1185-1188, 1996
13. Nichols AB, Owen J, Grossman BA, et al: Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 70:843-850, 1984
14. Jobes DR, Aitken GL, Shaffer GW: Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 110:36-45, 1995
15. Bull BS, Huse WM, Brauer FS, Korpman RA: Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69:685-689, 1975
16. Szalados JE, Ouriel K, Shapiro JR: Use of the activated coagulation time and heparin dose-response curve for the determination of protamine dosage in vascular surgery. J Cardiothorac Vasc Anesth 8:515-518, 1994